Subunit recombinant vaccine for the prevention of coronavirus infection

BIOLOGICAL2 trials

Sponsors

St. Petersburg Research Institute of Vaccines and Sera

Conditions

COVID-19COVID-19 Respiratory InfectionCoronavirus InfectionsImmunologic FactorsRespiratory Tract Infections

Phase 1

Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.

CompletedNCT05156723

St. Petersburg Research Institute of Vaccines and SeraCoronavirus Infections, COVID-19, Immunologic Factors +1

Start: 2021-07-19End: 2022-12-31Updated: 2023-08-30

Phase 2

Immunogenicity, Efficacy and Safety Trial of the Convacell Vaccine in Healthy Volunteers Aged 18 Years and Older

St. Petersburg Research Institute of Vaccines and SeraCoronavirus Infections, COVID-19, COVID-19 Respiratory Infection +1

Start: 2022-10-24End: 2023-12-30Target: 16304Updated: 2023-08-30

Related Papers

N-protein vaccine is effective against COVID-19: Phase 3, randomized, double-blind, placebo-controlled clinical trial.

2024-09-267 citations